PainReform Ltd (PRFX)

[Monksdream]

PRFX new 52 lo

[Tool_power]

Bunionectomy is just one of several applications for this 1st product. The market is actually quite substantial. They are targeting at least 10-12 countries. I’ll be buying more around $0.40.

[Monksdream]

More new lows to come this afternoon when I return from the supermarket

[BooDog]

Bonionectomy??? Isreal.... $4M @ .80????


wow. Not even looking any further on this one.

Surprised this isn't on the otc...


yet

I was stalking your "new 52 week lows"

[Monksdream]

PRFX new 52 lo

[Monksdream]

PRFX new 52 lo

[Tool_power]

PRFX: Looks like company raising funds now through selling of shares, which I don’t mind because they have a good business plan and they’re executing against it.

Buckle up, it’s gonna be a roller coaster ride!

[Monksdream]

PRFX new 52 lo

[Awl416]

What leaked?

[Monksdream]

PRFX over $3

[Sirpeter]

I'm wrong, only the first half of part 3 are complete...an earlier PR didn't tell us they were doing it this way...seems now the drug trial won't end until about Sept...oh well

[Sirpeter]

Drug trial should be nearly complete
...will help us

[Monksdream]

PRFX under $2

[Monksdream]

PRFX 10Q due March 14

[Sirpeter]

Come on back to PRFX...it needs you...up, up and away it's going

[Sirpeter]

PRFX is on the march...up 1,2,3,4....up 1,2,3,4

[Sirpeter]

Waking up for those who listen...( Actually I feel I'm talking to myself, if so, I will be the one making all d- money lol)

[Sirpeter]

Way oversold here...a big pop is coming soon

[Sirpeter]

GL

[surfer44]

Yeah, I like the story. Right now I'm going with "what is" and not "what if".

[Sirpeter]

PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced plans to commence the second part of the Company’s phase 3 trial to evaluate PRF-110 in patients undergoing bunionectomy surgery.

Starting the second part of the bunionectomy Phase III study follows the clearance by FDA of the DMF (Drug Master File) held by the Company’s API manufacturer. This second part of the trial is expected to proceed in the next quarter of 2023.

As announced earlier this year, the company completed the first part of its Phase 3 clinical trial of PRF-110, in which 15 patients undergoing bunionectomy surgery were enrolled at two clinical sites in Texas. The Company reported positive safety data in the first part of the Phase 3 clinical trial with no serious adverse events (SAEs) reported, suggesting a substantial potential advantage to using PRF-110 over opioids. As previously reported, PRF-110 provided pain reduction for up to 72 hours post-operatively in the Company’s prior Phase 2 proof-of-concept clinical study in herniorrhaphy (hernia repair).

The upcoming second part of the trial will be a double-blind study, in which the Company plans to randomize approximately 400 patients at seven clinical sites in the U.S.

PRF-110 is a highly uniform solution, resulting in consistent sustained and extended release of the analgesic. Ropivacaine, the active drug used in PRF-110, is a safe, well-tolerated, and well-characterized local anesthetic. The other components that comprise the remainder of the PRF-110 formulation have been designated by the FDA as Generally Recognized as Safe (GRAS), mitigating many potential safety issues common in drug development.

Key surgical benefits observed to date include:

PRF-110 does not alter the integrity of standard surgical devices, such as sutures and meshes used in a large variety of surgical procedures

PRF-110 does not interfere with normal macro and microscopic wound healing of surgical incisions in soft tissue and bone models

PRF-110 does not alter the tensile strength of healed skin at the surgical sites in an animal study mimicking surgical procedures

Ilan Hadar, Chief Executive Officer of PainReform, stated, “We expect to commence the second part of our phase 3 clinical study in Q4, 2023 following positive pharmacokinetic (PK) data in the first part of our Phase 3 clinical trial of PRF-110 in bunionectomy, which exceeded the FDA safety requirements.   This data reinforces the favorable results of our prior Phase 2 data in hernia repair, which provides us confidence in the outlook for PRF-110. Although we encountered delays due to issues experienced by the manufacturer of our API (active pharmaceutical ingredient), unrelated to PFR-110, we worked closely with them to rapidly resolve these matters, and our clinical program is now back on track. following a positive completion of the DMF review by the FDA. We look forward to advancing the trial, which we expect to complete and report the results by mid-2024. Importantly, we believe PRF-110 has the potential to address a significant unmet need in the multi-billion postoperative pain market with the potential to become standard of care as an alternative to systemic opioids.”

About PainReform

PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product is based on the local anesthetic ropivacaine, targeting the postoperative pain relief market. PRF-110 is an oil-based, viscous, clear solution deposited directly into the surgical wound bed before closure to provide localized and extended postoperative analgesia. The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, please visit www.painreform.com.

[surfer44]

I sold. Too speculative. And I need the money elsewhere. GL

[Sirpeter]

Starting to accumulate more...oversold

[Monksdream]

PRFX new 52 week low

[surfer44]

Just opened a small position. Interesting stock. Venture capital only...

[Sirpeter]

You said it buddy...it won't be for long

[Golden Cross]

Good deal

[Sirpeter]

Added more today

[TheGreenReaper]

Waiting on reversal.

[Golden Cross]

Looks bottomed

[Sirpeter]

Could be $100+ after phase 3 drug trial ends...soon

[Sirpeter]

It's a good day to add PRFX to your portfolio...it's dirt cheap

Enjoy yur day

[dinogreeves]

PRFX is undervalued, this price shouldn't be where it is now.

[BEIJING BILL]

good dey sir

[Sirpeter]

I add a little almost daily...very confident we're close

[TheGreenReaper]

Thought it was but not yet

[Sirpeter]

Going to the moon here...BUY BUY BUY!

[Sirpeter]

Yup...

[TheGreenReaper]

I have the feeling too and it feels like this week

[Sirpeter]

There will be another push very soon IMO

[TheGreenReaper]

It could happen the way it's trading

[TheGreenReaper]

Waiting on the rise here. Let's get it.

[Sirpeter]

This is a $20++ value play trading way cheap

[Sirpeter]

Guess I'm talking to myself here lol...if anyone out there is listening the longer the pennant formation, the SP will go...when this goes it will go

[Sirpeter]

After hrs trading looking good so far...could be a huge day

[Sirpeter]

Gains didn't hold... better days ahead...just not enough volume today

[Sirpeter]

Volume picking up

[TimeFades]

There it is

[Sirpeter]

BUY! BUY! BUY!

[Sirpeter]

OVERSOLD!